This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- ALT-2074
- DrugBank Accession Number
- DB05631
- Background
An organoselenium drug previously studied by Oxis International in Phase-II clinical trials for ulcerative colitis patients. Some indications of efficacy were demonstrated. BXT-51072 has enthusiastic endorsement for treatment in cardiovascular indications, primarily because of its ability to mimic the function of glutathione peroxidase.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for ALT-2074 (DB05631)
- Weight
- Average: 226.18
Monoisotopic: 227.021321249 - Chemical Formula
- C10H13NSe
- Synonyms
- Not Available
- External IDs
- ALT-2074
- BXT 51072
- BXT-51072
- SYI 2074
- SYI-2074
Pharmacology
- Indication
Investigated for use/treatment in cardiovascular disorders and diabetes mellitus type 1 and 2.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
2.08 (+/-0.17) hours.
- Clearance
24.15 (+/-2.38) (ml min-1kg-1).
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
IC50 2.0–2.6 μM.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareEltrombopag The bioavailability of ALT-2074 can be decreased when combined with Eltrombopag. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzenoids. These are aromatic compounds containing one or more benzene rings.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Not Available
- Sub Class
- Not Available
- Direct Parent
- Benzenoids
- Alternative Parents
- Azacyclic compounds / Organoselenium compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Hydrocarbon derivative / Organic nitrogen compound / Organoheterocyclic compound / Organonitrogen compound / Organopnictogen compound / Organoselenium compound
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 634U7OUR4R
- CAS number
- 173026-17-0
- InChI Key
- FXRYWOJYVGJZLE-UHFFFAOYSA-N
- InChI
- InChI=1S/C10H13NSe/c1-10(2)7-11-12-9-6-4-3-5-8(9)10/h3-6,11H,7H2,1-2H3
- IUPAC Name
- 4,4-dimethyl-3,4-dihydro-2H-1,2-benzoselenazine
- SMILES
- CC1(C)CN[Se]C2=CC=CC=C12
References
- General References
- Greenblatt DJ, Peters DE, Oleson LE, Harmatz JS, MacNab MW, Berkowitz N, Zinny MA, Court MH: Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol. 2009 Dec;68(6):920-7. doi: 10.1111/j.1365-2125.2009.03545.x. [Article]
- von Moltke LL, Greenblatt DJ, Schmider J, Harmatz JS, Shader RI: Metabolism of drugs by cytochrome P450 3A isoforms. Implications for drug interactions in psychopharmacology. Clin Pharmacokinet. 1995;29 Suppl 1:33-43; discussion 43-4. [Article]
- Link [Link]
- External Links
- ChemSpider
- 115187
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Acute Coronary Syndrome (ACS) / Type 2 Diabetes Mellitus 1 2 Completed Treatment Coronary Artery Disease (CAD) / Diabetes 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 5.81 mg/mL ALOGPS logP 1.65 ALOGPS logP 2.55 Chemaxon logS -1.6 ALOGPS pKa (Strongest Basic) 4.83 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 12.03 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 70.38 m3·mol-1 Chemaxon Polarizability 19.4 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 133.48503 predictedDeepCCS 1.0 (2019) [M+H]+ 137.3124 predictedDeepCCS 1.0 (2019) [M+Na]+ 146.37657 predictedDeepCCS 1.0 (2019)
Drug created at November 18, 2007 18:26 / Updated at June 12, 2020 16:52